Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1-2a Dose-Ranging Study of TLK286 in Combination With Doxil in Platinum Refractory or Resistant Ovarian Cancer

NCT00052065 is registered in ClinicalTrials.gov with Telik as lead sponsor.

NCT NCT00052065
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00052065 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1-2a Dose-Ranging Study of TLK286 in Combination With Doxil in Platinum Refractory or Resistant Ovarian Cancer
Lead sponsor
Telik
Phase
Phase 1/2
Overall status
Completed
Start date
February 28, 2003
Completion date
March 31, 2006
Enrollment
28
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian neoplasms